Paxlovid Found Not to Reduce Long COVID Risk
Drug Topics
JANUARY 4, 2024
A new study found that 16.1% of patients treated with nirmatrelvir-ritonavir (Paxlovid) reported long COVID symptoms, compared to 14% of untreated patients.
Drug Topics
JANUARY 4, 2024
A new study found that 16.1% of patients treated with nirmatrelvir-ritonavir (Paxlovid) reported long COVID symptoms, compared to 14% of untreated patients.
Pharmacy Times
JANUARY 4, 2024
Due to the observational nature of the study, the study authors said they cannot determine causal relationships between statins and cognitive decline for patients with Alzheimer disease.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JANUARY 4, 2024
In response to a surge in cases of COVID-19, flu, and RSV, hospitals are reinstating mask guidelines to avoid adverse capacity outcomes and staffing shortages seen in prior years.
Pharmacy Times
JANUARY 4, 2024
The risk of poor cognitive performance was nearly double in participants who had the greatest number of sleep disturbances compared to the least.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
JANUARY 4, 2024
Patients on a moderate carbohydrate diet increased their time in range by 4.7% and decreased their time above range by 5.9%.
Pharmacy Times
JANUARY 4, 2024
However, cognitive performance was not significantly worse than patients hospitalized for other conditions of a similar severity.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
JANUARY 4, 2024
Perhaps ashwagandha may aid in stress management, athletic performance, and sleep, but this effect is far from definitive.
STAT
JANUARY 4, 2024
The baby monitor didn’t go off. Any sound or motion in the twins’ room was supposed to set off an alarm — but in the wee hours of Nov. 27, 2022, Katie Czajkowski-Fell and Justin Fell weren’t woken up. They’d gotten it because of Hayden’s febrile seizures. These are common, generally nothing to worry about, the doctors said.
Pharmacy Times
JANUARY 4, 2024
Gepirone does not induce sexual dysfunction, a common limitation associated with SSRIs.
STAT
JANUARY 4, 2024
Delfi Diagnostics, a startup devising new ways to use routine blood draws to detect early signs of cancer, told STAT Thursday that it has appointed Susan Tousi, chief commercial officer for genomics giant Illumina, as its new CEO. She is the fourth senior executive to leave Illumina since June. Tousi will start next week, just in time for the J.P. Morgan Healthcare Conference , while founding CEO Victor Velculescu will remain on the company’s board to help guide its research programs.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Pharma
JANUARY 4, 2024
Use of Novo Nordisk and Eli Lilly’s popular diabetes and weight loss drugs come with warnings about a rare intestinal blockage condition called ileus, which can be life threatening. | Use of Novo Nordisk and Eli Lilly’s popular diabetes and weight loss drugs come with warnings about a rare intestinal blockage condition called ileus. Could cautions about more common side effects soon be added to the labels of popular treatments such as Novo’s Ozempic and Lilly’s Mounjaro?
STAT
JANUARY 4, 2024
Allogene Therapeutics is making unexpected changes to development plans for its off-the-shelf cell therapy for a type of blood cancer — a concession that competition from personalized CAR-T treatments, already entrenched in the market, has become more challenging. In a strategic pivot, two clinical trials involving patients with later-stage lymphoma are being shut down.
pharmaphorum
JANUARY 4, 2024
Amplifying the patient voice is essential for the success of clinical trials. Learn why it is crucial for patient engagement, recruitment, and overall trial success, and how it can address challenges such as transportation and financial barriers.
STAT
JANUARY 4, 2024
By the time his wife Glenda Daggert received a double organ transplant in 1999, Ira Copperman already had a lot of experience as a caregiver. The couple had been together for over two decades, married for one, and Copperman had become accustomed to helping Daggert manage her diabetes and its complications. Mixing insulin, going along for doctor’s visits, administering injections: it was all routine.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Store News
JANUARY 4, 2024
WBA’s first quarter sales increased 10% from the year-ago quarter to $36.7 billion, an increase of 8.7% on a constant currency basis.
STAT
JANUARY 4, 2024
Aera Therapeutics, a startup launched by the CRISPR pioneer Feng Zhang last year to solve one of the biggest bottlenecks in genetic medicine, has laid off a quarter of its staff, the company confirmed to STAT. The layoffs come as the biotech market remains mired in a now nearly three-year-long downturn that has left startups struggling to attract both private and public funds.
Fierce Pharma
JANUARY 4, 2024
Despite competitive pressure from a buzzy CRISPR therapy, bluebird bio keeps striding forward with its sickle cell disease gene therapy Lyfgenia. | Despite competitive pressure from a buzzy CRISPR therapy, bluebird bio has signed a second outcomes-based reimbursement agreement for its sickle cell gene therapy Lyfgenia.
STAT
JANUARY 4, 2024
Between condoms and vasectomies lies a vast, undeveloped chasm of male birth control. Contraline, a device startup that released early, positive clinical data in a press release on Thursday, hopes to fill it. The company has built an injectable gel that’s inserted into the sperm duct, physically blocking the sperm from coming out. Investigators tested the device on 23 participants in Australia last year and recorded no serious adverse events.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
JANUARY 4, 2024
Even after the heady highs of the COVID-19 era, the contract development and manufacturing organization (CDMO) realm remains one of biopharma's buzziest fields. | Even after the heady highs of the COVID era, the CDMO realm remains one of biopharma's buzziest fields. In 2024, CDMOs can advance their priorities on three fronts, a group of experts said during a recent Evaluate webinar on the state of the industry.
STAT
JANUARY 4, 2024
A new startup co-founded by CRISPR innovator Feng Zhang, a former executive at Grail and Illumina, and others has raised $57 million to develop a defanged form of gene editing that doesn’t cut the DNA strand. Moonwalk Therapeutics launched Thursday with funding from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, Khosla Ventures, GV, and YK Bioventures.
Fierce Healthcare
JANUARY 4, 2024
The cost of treating a COVID-19 hospital patient in the hospital rose by 26% over the first two years of the pandemic, more than five times the rate of medical inflation during that time, according | On average and after adjustments, direct treatment costs for a COVID-19 hospital admission rose 26%, from $10,394 in March 2020 to $13,072 in March 2022, researchers found in a new analysis of 1.3 million inpatient stays.
STAT
JANUARY 4, 2024
The J.P. Morgan Healthcare Conference is upon us, bringing its frenetic meetings, crowded hallways, and hotel rooms so expensive that even the pharmaceutical industry complains about what a free market does to the prices of scarce goods. This year’s iteration, starting Monday in San Francisco, finds the biotech industry, in particular, in a curious spot.
Pharmacy Times
JANUARY 4, 2024
The efficacy of biologics suggests a potential for biologic-based treatment for patients with asthma-chronic obstructive pulmonary disease overlap.
STAT
JANUARY 4, 2024
Novo Nordisk may already have one blockbuster obesity drug in its portfolio, but the Danish drugmaker has actively begun searching out others, including through a new partnership announced Thursday. Novo Nordisk will work with Omega Therapeutics, a startup founded by venture creation firm Flagship Pioneering, to develop a genetic editing treatment for obesity.
Fierce Pharma
JANUARY 4, 2024
Already with a manufacturing site in Chiba, Japan, AGC Biologics is doubling down on its presence in the country with a new facility in Yokohama. | Already with a manufacturing site in Chiba, Japan, AGC Biologics is doubling down on its presence in the country with a new facility in Yokohama. The Seattle-based CDMO has unveiled its plan to construct a four-story complex, which will cover 20,000 square meters (215,000 square feet) and is expected to become operational in 2026.
STAT
JANUARY 4, 2024
Several advocacy groups are blasting a Food and Drug Administration proposal to work with a Denver Health surveillance system for monitoring misuse of prescription opioids over long-standing ties the operation has to the pharmaceutical industry. At issue is the Research, Abuse, Diversion, and Addiction-Related Surveillance system, or RADARS, which was originally created as in-house monitoring program by Purdue Pharma and later sold to the Denver Health and Hospital Authority.
Fierce Pharma
JANUARY 4, 2024
This year, CVS Health plans to employ the classic "out with the old, in with the new" mantra when it comes to AbbVie’s Humira. | The changes to major commercial formularies will take effect April 1 and favor Humira biosimilar options over the branded drug as part of CVS' efforts to ramp up U.S. biosimilar adoption.
STAT
JANUARY 4, 2024
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will draw on a bit of insight from the Morning Mayor, who taught us that “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us.
Drug Store News
JANUARY 4, 2024
Ulta Beauty’s Ultamate Rewards loyalty program will now be known as Ulta Beauty Rewards.
STAT
JANUARY 4, 2024
Health tech hopefuls might once have been used to a wealth of job options, especially in the pandemic’s early stages when investors pumped record-breaking dollar amounts into an unprecedented number of ventures. That glut of opportunities meant workers could bargain harder for better job offers, demanding perks and flexibilities like permanent remote work or expensive fertility benefits.
pharmaphorum
JANUARY 4, 2024
Scientists at Roche and Harvard University have discovered a new class of antibiotic that can kill carbapenem-resistant Acinetobacter baumannii (CRAB), a major public health threat
STAT
JANUARY 4, 2024
WASHINGTON — UCB left BIO at the end of 2023, the second major member company to exit after Pfizer pulled out as well. UCB, headquartered in Belgium, decided not to renew its BIO membership after a routine evaluation of its engagement in trade associations, said company spokesperson Erica Puntel. Pfizer, whose departure STAT reported first , was listed on BIO’s website as a sponsor at one of the group’s highest levels.
pharmaphorum
JANUARY 4, 2024
Digital health company Click Therapeutics has won an FDA breakthrough device designation for CT-155, a digital therapeutic (DTx) for the negative symptoms of schizophrenia, like social withdrawal and apathy, that tend not to respond well to antipsychotic drugs.
Let's personalize your content